REGN - Biotech Investing In A Time Of The Coronavirus

• A broad and diverse effort is underway by biotech companies to solve the terrible riddle of the Coronavirus.
• Firms are forging ahead with testing, treatment and vaccine research and product development.
• Results of even the most promising treatments, however, are not yet clear cut. Even those that may be are not proof a bullish thesis for those companies that have developed them.
• Biotech investing is risky. The temptations of building a large position in a COVID 19-engaged public company are obvious.
• A wise investor would be well-served by opening or adding to such positions with a measure of caution.

For further details see: